Monte Rosa Therapeutics (GLUE) Cash & Equivalents (2020 - 2026)

Monte Rosa Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $678.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 763.48% year-over-year to $678.1 million; the TTM figure through Mar 2026 stood at $678.1 million (up 763.48% YoY), while the FY2025 annual figure was $129.9 million, down 65.91% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $678.1 million, up from $129.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $678.1 million in Q1 2026, with the low at $47.0 million in Q2 2023.
• The 5-year median for Cash & Equivalents is $112.4 million (2022), against an average of $176.4 million.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents sank 84.13% in 2022, then soared 763.48% in 2026.
• Monte Rosa Therapeutics' Cash & Equivalents stood at $54.9 million in 2022, then surged by 133.28% to $128.1 million in 2023, then surged by 197.39% to $381.0 million in 2024, then sank by 65.91% to $129.9 million in 2025, then soared by 422.08% to $678.1 million in 2026.
• Business Quant data shows GLUE's Cash & Equivalents at $678.1 million in Q1 2026, $129.9 million in Q4 2025, and $401.6 million in Q3 2025.